Low-dose chemotherapy for advanced head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a low-dose, continuous chemotherapy approach (called metronomic therapy) using two drugs, cyclophosphamide and etoposide, for people with advanced or recurrent head and neck cancer that has not responded to first-line treatment. The goal is to see if this treatment can help control the cancer when standard options have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have head and neck cancer that has come back after treatment, or has spread or is advanced.
- Your cancer must have not responded to or worsened after your first round of chemotherapy.
- This trial is not for people whose cancer is only being treated as an initial treatment (before or after surgery or radiation).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (toripalimab) and two chemotherapy drugs (cisplatin and docetaxel) as a first treatment before surgery or radiation for advanced head and neck cancers. It may help shrink tumors that can't be easily treated with standard therapy.
This trial tests a combination of low-dose radiation and an immunotherapy drug (similar to Keytruda) given before surgery for advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of targeted therapy (cetuximab) and immunotherapy (avelumab) plus chemotherapy as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if adding these medicines helps control the cancer longer.
This trial tests a combination of three drugs—docetaxel (a chemotherapy), nimotuzumab (a targeted therapy), and pucotenlimab (an immunotherapy)—for people with head and neck cancer that has returned or spread and has not responded to standard treatments. The goal is to see if this three-drug combination can help shrink tumors or slow the cancer's growth.
This trial tests a custom treatment plan for people with advanced head and neck cancer that is not caused by HPV. It combines radiation and chemotherapy with a targeted drug called cetuximab, adjusted based on your tumor's characteristics.
This trial compares two cisplatin dosing schedules (weekly low-dose vs higher dose less often) given alongside radiation for certain head and neck cancers. It’s testing which schedule works well while keeping side effects manageable during planned, curative-intent radiation.
Hear when a new Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.